- Home
- CTNT vs GLTO Comparison
CTNT vs GLTO Comparison
Compare CTNT & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNT
- GLTO
- Stock Information
- Founded
- CTNT 2016
- GLTO 2011
- Country
- CTNT United States
- GLTO Denmark
- Employees
- CTNT N/A
- GLTO N/A
- Industry
- CTNT
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- CTNT
- GLTO Health Care
- Exchange
- CTNT Nasdaq
- GLTO Nasdaq
- Market Cap
- CTNT 5.0M
- GLTO 4.0M
- IPO Year
- CTNT 2023
- GLTO 2020
- Fundamental
- Price
- CTNT $1.32
- GLTO $3.20
- Analyst Decision
- CTNT
- GLTO Buy
- Analyst Count
- CTNT 0
- GLTO 1
- Target Price
- CTNT N/A
- GLTO $10.00
- AVG Volume (30 Days)
- CTNT 32.1K
- GLTO 82.7K
- Earning Date
- CTNT 05-05-2025
- GLTO 05-08-2025
- Dividend Yield
- CTNT N/A
- GLTO N/A
- EPS Growth
- CTNT N/A
- GLTO N/A
- EPS
- CTNT N/A
- GLTO N/A
- Revenue
- CTNT $858,770.00
- GLTO N/A
- Revenue This Year
- CTNT N/A
- GLTO N/A
- Revenue Next Year
- CTNT $25.00
- GLTO N/A
- P/E Ratio
- CTNT N/A
- GLTO N/A
- Revenue Growth
- CTNT N/A
- GLTO N/A
- 52 Week Low
- CTNT $1.20
- GLTO $2.01
- 52 Week High
- CTNT $15.15
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- CTNT 40.32
- GLTO 57.26
- Support Level
- CTNT $1.38
- GLTO $3.05
- Resistance Level
- CTNT $1.70
- GLTO $3.38
- Average True Range (ATR)
- CTNT 0.10
- GLTO 0.25
- MACD
- CTNT -0.01
- GLTO 0.04
- Stochastic Oscillator
- CTNT 5.00
- GLTO 74.83
About CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: (i) cargo storage, (ii) freight forwarding, (iii) U.S. customs clearance, and (iv) labor services and cargo loading and unloading.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.